Eight years sitting across the desk from real people, reviewing real portfolios, and watching real money either grow or ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...